(bictegravir sodium + emtricitabine + tenofovir alafenamide)

all catalysts(0)

nothing on the calendar yet

News(6)

• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 6d ago
• Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
  HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
  biospace · 6d ago
• Merck stages expanded access to monthly HIV PrEP pill ahead of approval
  Following in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.
  fiercebiotech · 19d ago
• Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
  A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…
  biopharma_dive · 20d ago
• STAT+: Sales from controversial U.S. drug discount program rose to $100 billion last year
  Prescription drugs purchased under a controversial government discount program amounted to $100 billion in 2025, a 22.8% increase from the previous year.
  stat · 28d ago
• Merck adds to pharma’s AI push; Roche details MS drug results
  Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…
  biopharma_dive · 3mo ago